Epidemiology and Risk Factors for Invasive Fungal Infections in Pancreas Transplant in the Absence of Postoperative Antifungal Prophylaxis

• Published in: Open forum infectious diseases 2023-11, Vol.10 (11), p.ofad478-ofad478
• Main Authors: Zachary, Jessica, Chen, Jeanne M, Sharfuddin, Asif, Yaqub, Muhammad, Lutz, Andrew, Powelson, John, Fridell, Jonathan A, Barros, Nicolas
• Format: Article
• Language: English
• Subjects: Major
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofad478

Abstract Background Invasive fungal infections (IFIs) remain a rare yet dreaded complication following pancreas transplantation. Current guidelines recommend antifungal prophylaxis in patients with 1 or more risk factors. At our center, single-dose antifungal prophylaxis is administered in the operating room but none subsequently, regardless of risk factors. Here we evaluate the 1-year incidence, outcome, and risk factors associated with IFI following pancreas transplantation. Methods A retrospective, single-center cohort study was conducted in patients who underwent pancreas transplantation between 1 January 2009 and 31 December 2019. Records were manually reviewed, and cases were adjudicated using consensus definitions. The 1-year cumulative incidence, mortality, and risk factors were analyzed by Kaplan-Meier method and differences between populations were assessed with Fisher test and Mann-Whitney U test. Results Three hundred sixty-nine recipients were included. Twelve IFIs were identified: candidiasis (8), aspergillosis (2), histoplasmosis (1), and cryptococcosis (1). Intra-abdominal infections were the most common presentation (5), followed by bloodstream infections (3), disseminated disease (2), pulmonary disease (1), and invasive fungal sinusitis (1). Median time to IFI was 64 days (interquartile range, 30–234 days). One-year cumulative incidence was 3.25% (95% confidence interval, 1.86%–5.65%). There were no significant differences between patients with or without IFI regarding type of transplant (P = .17), posttransplant dialysis (P = .3), rejection (P = .5), cytomegalovirus serostatus (P = .45), or reoperation (P = .19). For patients with IFI, the 1-year graft and patient survival rates were 58% versus 95% (P < .0001) and 75% versus 98.6% (P < .001), respectively. Conclusions Our study suggests that the use of a single-dose antifungal prophylaxis administered in the operating room but none subsequently does not result in an increased incidence of IFI following pancreas transplantation. Graphical Abstract Graphical abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/epidemiology-and-risk-factors-for-invasive-fungal-infections-in-pancreas-transplant-in-the-absence-of-post-operative-antifungal-prophylaxis-f903a48a-e49a-42bd-a33b-49b3c7312c83 Invasive fungal infections (IFIs) remain a dreaded complication following pancreas transplantation. At our center, single-dose antifungal prophylaxis is administered in th